| Literature DB >> 32824985 |
Jong-Hoon Lee1, Ha Kyeu An2, Mun-Gi Sohn3, Paul Kivela4, Sangsuk Oh5.
Abstract
The aim of this study is to examine the use of an inflammasome competitor as a preventative agent. Coronaviruses have zoonotic potential due to the adaptability of their S protein to bind receptors of other species, most notably demonstrated by SARS-CoV. The binding of SARS-CoV-2 to TLR (Toll-like receptor) causes the release of pro-IL-1β, which is cleaved by caspase-1, followed by the formation and activation of the inflammasome, which is a mediator of lung inflammation, fever, and fibrosis. The NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome is implicated in a variety of human diseases including Alzheimer's disease (AD), prion diseases, type 2 diabetes, and numerous infectious diseases. By examining the use of 4,4'-diaminodiphenyl sulfone (DDS) in the treatment of patients with Hansen's disease, also diagnosed as Alzheimer's disease, this study demonstrates the diverse mechanisms involved in the activation of inflammasomes. TLRs, due to genetic polymorphisms, can alter the immune response to a wide variety of microbial ligands, including viruses. In particular, TLR2Arg677Trp was reported to be exclusively present in Korean patients with lepromatous leprosy (LL). Previously, mutation of the intracellular domain of TLR2 has demonstrated its role in determining the susceptibility to LL, though LL was successfully treated using a combination of DDS with rifampicin and clofazimine. Of the three tested antibiotics, DDS was effective in the molecular regulation of NLRP3 inflammasome activators that are important in mild cognitive impairment (MCI), Parkinson's disease (PD), and AD. The specific targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by DDS may be responsible for its observed preventive effects, functioning as a competitor.Entities:
Keywords: 4,4′-diaminodiphenyl sulfone (dapsone); AD; Alzheimer’s disease; DDS; LL; MADDS; MPO; NACHT, LRR and PYD domains-containing protein 3; NLRP3; TLR; lepromatous leprosy (also known as Hansen’s disease); monoacetyldapsone; myeloperoxidase; toll-like receptor
Mesh:
Substances:
Year: 2020 PMID: 32824985 PMCID: PMC7503668 DOI: 10.3390/ijms21175953
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
The clinical manifestations of SARS-CoV-2 and DDS in humans.
| Clinical Manifestations | Sars-Cov-2 Symptoms | DDS Symptoms |
|---|---|---|
| skin vascular symptom | (i) violaceous macules with porcelain appearance, (ii) livedo of the trunk with chest pain and cough, (iii) violaceous macule and Raynaud’s phenomenon 10 days after fever and cough, (iv) necrotic purpura in a patient treated with leflunomide and systemic steroids for rheumatoid arthritis, (v) chilblain appearance and Raynaud’s phenomenon in a patient with anosmia, fever and cough, (vi) eruptive cherry angioma 21 days after COVID-19 healing of clinical symptoms [ | “glandular fever”: (i) fever, (ii) lymphadenopathy, (iii) generalized rash, and (iv) hepatitis occurring after dapsone intake [ |
| hypersensitivity reactions | SARS-CoV-2 symptoms are like a severe idiosyncratic DDS reaction characterized by the clinical triad of fever, rash, and systemic involvement, which can cause severe organ (heart, kidney, lung, brain, etc.) dysfunction [ | the syndrome is a severe idiosyncratic DDS reaction characterized by the clinical triad of fever, rash, and systemic involvement (most commonly of the liver and the hematologic system), which can cause severe organ dysfunction [ |
| hematology laboratory | focal fibrin clusters mixed with mononuclear inflammatory cells, decreased eosinophils, decreased lymphocytes, increased neutrophils [ | leukocytosis, eosinophilia [ |
| anemia | thrombocytopenia, consumptive coagulopathy [ | hemolytic anemia and methemoglobinemia [ |
| liver disease, pancreatic disease | clinically significant liver injury is uncommon [ | hepatitis/liver toxicity [ |
| renal disease | severe collapsing focal segmental glomerulosclerosis, acute tubular necrosis [ | acute renal failure [ |
| cardiac disease | acute myocardial injury and chronic damage to the cardiovascular system [ | myocarditis, dapsone-induced hypersensitivity syndrome-associated complete atrioventricular block [ |
| pulmonary disease | coronavirus disease (COVID-19)-related pneumonia [ | pneumonitis [ |
| neurologic disease | large-vessel stroke [ | recovery of dementia syndrome following treatment of brain inflammation [ |
Figure 1Nucleophilic properties of, 4′-diaminodiphenyl sulfone (DDS). Proteins contain many nucleophilic sites capable of attacking a ubiquitin (Ub)-conjugating enzyme (E2)–Ub thioester linkage and undergoing ubiquitination. The best-described sites are the amine-containing internal lysine residues and the free amine of the N-terminus of the polypeptide backbone. Ub is activated by an Ub-activating (E1) enzyme, using energy from ATP hydrolysis, and passed to an Ub-conjugating (E2) enzyme. Ub can then be passed to a substrate protein, specified by the distinct E3 ligase that binds both the substrate and the E2. DDS can compete with the ubiquitination cascade. Cysteine thiols and hydroxyls on serines, threonines, leucines, and tyrosines could also potentially be ubiquitinated by an identical mechanism [41,43,44].
Figure 2Possible schematic diagram: blocking of SARS-CoV-2 by DDS.
Hansen’s disease recurrences and prevalence of respiratory infectious disease.
| Cumulative Recurrence Risk Index | Infectious Respiratory Diseases | |||||
|---|---|---|---|---|---|---|
| Year | Inactive Patient | Number of Recurrent Patients | Annual Recurrence Rate (%) | DDS Intake | Infected Person | Remarks |
| 2002 SARS-CoV | 16,712 | 10 | 0.05 | -(0 person) | (no prevalence) | |
| 2003 | 16,283 | 6 | 0.03 | - | - | |
| 2004 | 15,797 | 6 | 0.03 | - | - | |
| 2005 | 15,350 | 5 | 0.03 | - | - | |
| 2006 | 14,851 | 5 | 0.03 | - | - | |
| 2007 | 14,321 | 3 | 0.02 | - | - | |
| 2008 | 13,875 | 3 | 0.02 | - | - | |
| 2009 Influenza A virus subtype H1N1 | 13,422 | 3 | 0.02 | -(0 person) | (no prevalence) | |
| 2010 | 13,033 | 7 | 0.05 | - | - | |
| 2011 | 12,582 | 3 | 0.02 | - | - | |
| 2012 | 12,068 | 1 | 0.01 | - | - | |
| 2013 | 11,595 | 1 | 0.01 | - | - | |
| 2014 | 11,104 | 1 | 0.01 | - | - | |
| 2015 MERS | 10,653 | 1 | 0.01 | -(0 person) | (no prevalence) | |
| 2016 | 10,236 | - | - | - | - | |
| 2017 | 9908 | - | - | - | - | |
| 2018 | 9503 | 1 | 0.01 | 2019–2020.6. | - | - |
| 2019 SARS-CoV-2 | 9160 | 2 | 0.02 | -(0 person) | (no prevalence) | |
| –2020. 6.30. SARS-CoV-2 | -(0 person) | (no prevalence) | ||||
Figure 3Respiratory infectious diseases (RIS) of Hansen’s patients at Sorokdo National Hospital in Korea. International Classification of Diseases (ICD-9, 10) of RIS are J00 (acute nasopharyngitis), J01 (acute sinusitis), J01.8 (other acute sinusitis), J02 (acute pharyngitis), J02.9 (acute pharyngitis, unspecified), J03 (acute tonsillitis), J03.0 (streptococcal tonsillitis), J03.9 (acute tonsillitis, unspecified), J04.0 (acute laryngitis), J06.0 (acute laryngopharyngitis), J06.9 (acute upper respiratory infection, unspecified), J09 (influenza due to identified zoonotic or pandemic influenza virus), J10.8 (influenza with other manifestations, seasonal influenza virus identified), J12.9 (viral pneumonia, unspecified), J15.8 (other bacterial pneumonia), J15.9 (bacterial pneumonia, unspecified), J18.0 (bronchopneumonia, unspecified), J18.9 (pneumonia, unspecified), J20.9 (acute bronchitis, unspecified), J31 (chronic rhinitis, nasopharyngitis and pharyngitis), J31.0 (chronic rhinitis), J31.1 (chronic nasopharyngitis), J31.2 (chronic pharyngitis), J32 (chronic sinusitis), J32.4 (chronic pansinusitis), J32.8 (other chronic sinusitis), J35. 0 (chronic tonsillitis), J37.0 (chronic laryngitis). This is a graph that can guess the characteristics of DDS as a competitor when comparing the proportion of RIS with those who have been prescribed DDS. After President Dae-Jung Kim came to power in 1998, Hansen’s patients were given freedom. Many were devout Christians, but as more and more became smokers, as in a typical rural village, RIS increased. Sorok-do became a tourist destination and travelers have come and gone freely, but SARS-CoV (2002), influenza A virus subtype H1N1 (2009), MERS (2015), and SARS-CoV-2 (2020) have not occurred.
Age distribution of Hansen’s disease in Korea (2019): Hansen’s disease status and major indicators.
| Total | Age | Average Age | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–19 | 20–39 | 40–59 | 60–79 | 80– | SUM | Treatment Place | |||||
| Home | Town | Nursing | Hospital | ||||||||
| total | 9288 | - | 18 | 545 | 5147 | 3578 | 79 | 78 | 80 | 81 | 78 |
| Active leprosy patients | 128 | - | 7 | 9 | 79 | 33 | 71 | 73 | 68 | 65 | 77 |
Treatment of neuroinflammation with anti-Alzheimer’s disease drug (AAD) used as a new biomarker of numeric clinical staging (NCS)—a new biomarker of numeric clinical staging (NCS) is denoted as (D). (D) (added NCS is italicized) (Supplement. 2).
| Year | NCS |
|
|---|---|---|
| 2007 | Stage 2 | |
| 2008.02.05 | Stage 3 | |
|
| ||
|
| ||
| 2018.06.27 | Stage 4 | |
|
|
|
|
|
|
|
|
| 2018.11.06 | Stage 5 | |
|
|
| |
|
|
|
|
|
| ||
|
| ||
| 2019.01.14 | Stage 3 | |
| 2020.03.18 | Stage 3 |
|